📊 Get daily AI-graded market briefings
Morning + evening · AI impact + sector exposure · Free
LAST 30 DAYS
0 articles
AVG GRADE
HIGH
score: 0.50
SENTIMENT
BULLISH
TOTAL VIEWS
8
RLMD Latest News & AI Sentiment Analysis
0 articles · Grade: HIGH · Real-time AI-graded coverage
RECENT COVERAGE · 2 ARTICLES
Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript
RLMD released Q2 2026 earnings results via earnings call on August 6, 2026. The company is a clinical-stage therapeutics developer...
Relmada Therapeutics Appoints CNS Drug Development Veteran Michael Quirk as Senior Advisor for Sepranolone Program
RLMD has appointed Dr. Michael Quirk, a CNS drug development veteran with 20+ years of neuroscience expertise and prior CSO tenure at...
RELATED TICKERS
E
ESEN Analytics
AI-powered equity research platform covering 5,000+ US equities. Our proprietary AI grading system (A+ to D scale) analyzes fundamentals, technicals, and news sentiment daily. Coverage data updated every 24 hours.
Learn about our methodology →
ⓘ AI-graded news coverage · Not investment advice